Patents by Inventor Kazuyasu Nakamura

Kazuyasu Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for producing recombinant antibody and antibody fragment thereof
    Patent number: 8632996
    Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: January 21, 2014
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20130337505
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a method for producing a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: March 23, 2012
    Publication date: December 19, 2013
    Applicant: KYOWA HAKKO KIRIN, CO., LTD.
    Inventors: Eisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI
  • HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF
    Publication number: 20130273038
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Application
    Filed: April 22, 2013
    Publication date: October 17, 2013
    Inventors: Kenya SHITARA, Kazuyasu NAKAMURA, Emi HOSAKA, Akiko SHIMIZU, Masamichi KOIKE
  • ANTI-CD4 ANTIBODY
    Publication number: 20130177944
    Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.
    Type: Application
    Filed: January 31, 2013
    Publication date: July 11, 2013
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Tomoaki NAKAGAWA, Sayaka HORI, Rinpei NIWA, Tsuguo KUBOTA, Kazuhiro MASUDA, Kazuyasu NAKAMURA
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 8481039
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: July 9, 2013
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • Anti-CD4 antibody
    Patent number: 8399621
    Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: March 19, 2013
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Tomoaki Nakagawa, Sayaka Hori, Rinpei Niwa, Tsuguo Kubota, Kazuhiro Masuda, Kazuyasu Nakamura
  • Cells with altered fucosylation and producing antibodies therefrom
    Patent number: 8367407
    Abstract: The present invention relates to a cell and mammal in which GDP-mannose 4,6-dehydratase is knocked-out. The cell and mammal are useful for the production of an antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, such as an antibody useful for treating various diseases. The cell and mammal are also useful for the production of a fragment of the antibody, and a fusion protein having the Fc region of the antibody.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: February 5, 2013
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Antibody composition-producing cell
    Patent number: 8329443
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: December 11, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Method of enhancing of binding activity of antibody composition to Fc? receptor IIIa
    Patent number: 8313913
    Abstract: A method for enhancing a binding activity of an antibody composition to Fc? receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fc? receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: November 20, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Kazuyasu Nakamura, Kenya Shitara
  • GENE RECOMBINANT ANTIBODY AND ANTIBODY FRAGMENT THEREOF
    Publication number: 20120276090
    Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
    Type: Application
    Filed: June 8, 2012
    Publication date: November 1, 2012
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenya SHITARA, Nobuo HANAI, Emi SHOJI, Mikiko SAKURADA, Akiko FURUYA, Kazuyasu NAKAMURA, Rinpei NIWA, Kenji SHIBATA, Motoo YAMASAKI
  • ANTI-TROP-2 ANTIBODY
    Publication number: 20120237518
    Abstract: The present invention relates to a monoclonal antibody or an antibody fragment thereof, which binds to the extracellular region of human Trop-2 with high affinity and exhibits high ADCC activity and high antitumor activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent or a diagnostic agent using the antibody fragment thereof.
    Type: Application
    Filed: June 10, 2011
    Publication date: September 20, 2012
    Applicants: KYOWA HAKKO KIRIN CO., LTD, SAPPORO MEDICAL UNIVERSITY
    Inventors: Miki YAMAGUCHI, Kazunori Kato, Hirofumi HAMADA, Kazuyasu NAKAMURA, Yoshiyuki SUGIMOTO, Tsuguo KUBOTA, Masahiro IKEDA
  • HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF
    Publication number: 20120177643
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Application
    Filed: March 23, 2012
    Publication date: July 12, 2012
    Applicant: Kyowa Hakko Kirin Co., LTD.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20120177649
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: February 3, 2012
    Publication date: July 12, 2012
    Applicant: KYOWA HAKKO KIRIN, CO., LTD.
    Inventors: Eisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI
  • Method for treating the Th2-mediated disease
    Patent number: 8197814
    Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: June 12, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 8173781
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: May 8, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 8163282
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: April 24, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • Glycoengineered, recombinant antibody
    Patent number: 8158760
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: April 17, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Human CDR-grafted antibody and antibody fragment thereof
    Patent number: 8143058
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: March 27, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody
    Patent number: 8110195
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody binding to ganglioside GM2, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: February 7, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Motoo Yamasaki, Nobuo Hanai, Emi Hosaka, Kazuya Yamano
  • Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation
    Patent number: 8101185
    Abstract: The present invention relates to a cell for the production of an anti-IL-5 antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: January 24, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Motoo Yamasaki, Nobuo Hanai, Emi Hosaka, Kazuya Yamano